Cybin is trading 5.2% up at $10.92, though available coverage does not directly link the move to a specific catalyst. - On October 15, the company announced it appointed Dr. Suresh Durgam to its board. - Cybin cited his CNS drug-development experience and history helping secure FDA approvals. - Biotech shares are also higher, with the XBI up 2.20%, providing supportive sector context.